252 related articles for article (PubMed ID: 24428757)
1. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway.
Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W
J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757
[TBL] [Abstract][Full Text] [Related]
2. A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways.
Zhuang C; Sheng C; Shin WS; Wu Y; Li J; Yao J; Dong G; Zhang W; Sham YY; Miao Z; Zhang W
Oncotarget; 2014 Nov; 5(21):10830-9. PubMed ID: 25350970
[TBL] [Abstract][Full Text] [Related]
3. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
4. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways.
Dey A; Tergaonkar V; Lane DP
Nat Rev Drug Discov; 2008 Dec; 7(12):1031-40. PubMed ID: 19043452
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.
Christner SM; Clausen DM; Beumer JH; Parise RA; Guo J; Huang Y; Dömling AS; Eiseman JL
Cancer Chemother Pharmacol; 2015 Aug; 76(2):287-99. PubMed ID: 26050209
[TBL] [Abstract][Full Text] [Related]
6. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
Vaupel A; Holzer P; Ferretti S; Guagnano V; Kallen J; Mah R; Masuya K; Ruetz S; Rynn C; Schlapbach A; Stachyra T; Stutz S; Todorov M; Jeay S; Furet P
Bioorg Med Chem Lett; 2018 Nov; 28(20):3404-3408. PubMed ID: 30217415
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of novel inhibitors of the MDM2-p53 interaction.
Rew Y; Sun D; Gonzalez-Lopez De Turiso F; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Deignan J; Fox BM; Gustin D; Huang X; Jiang M; Jiao X; Jin L; Kayser F; Kopecky DJ; Li Y; Lo MC; Long AM; Michelsen K; Oliner JD; Osgood T; Ragains M; Saiki AY; Schneider S; Toteva M; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
J Med Chem; 2012 Jun; 55(11):4936-54. PubMed ID: 22524527
[TBL] [Abstract][Full Text] [Related]
10. Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
He S; Dong G; Wu S; Fang K; Miao Z; Wang W; Sheng C
J Med Chem; 2018 Aug; 61(16):7245-7260. PubMed ID: 30045621
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.
Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J
Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
[TBL] [Abstract][Full Text] [Related]
13. Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signaling.
Hwang SG; Park J; Park JY; Park CH; Lee KH; Cho JW; Hwang JI; Seong JY
PLoS One; 2012; 7(9):e44259. PubMed ID: 23028510
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
[TBL] [Abstract][Full Text] [Related]
15. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
[TBL] [Abstract][Full Text] [Related]
17. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
18. Lipopolysaccharide downregulates the expression of p53 through activation of MDM2 and enhances activation of nuclear factor-kappa B.
Odkhuu E; Mendjargal A; Koide N; Naiki Y; Komatsu T; Yokochi T
Immunobiology; 2015 Jan; 220(1):136-41. PubMed ID: 25172547
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]